- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Latest News
Dr. Gurpreet Sandhu, CEO of Reva Pharma delivered lecture on “Healthcare & Pharmaceutical Trends in Indiaâ€...
Read More
Read More
As an annual feature Reva Pharma, participated at Japan (CPhI). A lecture was delivered by Dr. Sandhu on...
Read More
Read More
Reva Pharma was represented by Dr Sandhu at the 34th Annual AAPI Convention at New York. The AAPI (American Association...
Read More
Read More
The 1st INDIA-JAPAN MEDICAL PRODUCTS REGULATION SYMPOSIUM was conducted on 18th & 19th May 2016 at New Delhi. The...
Read More
Read More
CPhI Japan, which was held during April 20–22, 2016, at the Big Sight Exhibition Centre, Tokyo, marks its 15th...
Read More
Read More
AMBASSADORS’ MEET Venue: ITC Maurya, New Delhi
The meet was organized by Pharmexcil {Ministry of...
Read More
The meet was organized by Pharmexcil {Ministry of...
Read More
Dr Gurpreet Sandhu (Managing Director -- Reva Pharma) & Honorary Advisor (Pharmexcil); conducted meeting with Gilead...
Read More
Read More
The Global Partnership for Health: U.S.-India Collaboration in Pharmaceutical Manufacturing and Research &...
Read More
Read More
As per the companies midterm strategy plan "Reva Pharma" has taken Afghanistan as the next emerging market in its vision...
Read More
Read More
In the second half of the Pre-Connect Congress held a day before the official opening of CPhI Worldwide, experts and...
Read More
Read More
"A wide perspective, regarding the application of data integrity principles, should be applied in order to include all...
Read More
Read More
Gurpreet Sandhu - Reva Pharma
The CPhI report predicts a possible NCE new chemical entity from India...
Read More
The CPhI report predicts a possible NCE new chemical entity from India...
Read More